FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to treat cancer. For this purpose, a therapeutically effective amount of a PEG-IL-10 agent is administered to a person, in which the indicated amount is sufficient to maintain an average residual concentration of IL-10 in serum of at least 1.0 ng/ml for a period of at least 1 week, wherein the average residual concentration of IL-10 in serum is maintained for at least 90 % of the specified period of time.
EFFECT: method allows to increase the effectiveness of treatment of cancer and prevent cancer due to the achievement of the required residual concentration of IL-10 in serum.
15 cl, 3 dwg, 18 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARING AND USING MONO- AND DI-PEGYLATED IL-10 | 2009 |
|
RU2549702C2 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| CONSTRUCTED CELLS, EXPRESSING MULTIPLE IMMUNOMODULATORS, AND THEREOF APPLICATION | 2009 |
|
RU2573912C2 |
| RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| NEW LIGAND OF CYTOKINE RECEPTOR ZCYTOR17 | 2003 |
|
RU2490276C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2017 |
|
RU2778811C2 |
